Dicerna Pharmaceuticals, Inc. (DRNA) Analysts See $-0.42 EPS

July 14, 2018 - By Mary Markley

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) LogoInvestors sentiment decreased to 2.44 in Q1 2018. Its down 0.56, from 3 in 2017Q4. It turned negative, as 3 investors sold Dicerna Pharmaceuticals, Inc. shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported.
Element Cap Mgmt Limited Liability Corporation holds 0.02% or 82,957 shares in its portfolio. Renaissance Techs Limited Liability reported 289,400 shares. State Street has 22,583 shares for 0% of their portfolio. Bridgeway Cap Mngmt Inc holds 83,300 shares. 246,411 were accumulated by Emory University. Fmr Ltd Liability Corp has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers Tru holds 151,571 shares or 0.06% of its portfolio. Bank Of New York Mellon Corp owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 41,432 shares. The New Jersey-based Caxton has invested 0.15% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Blackrock reported 0% stake. Barclays Public Limited Co accumulated 41,590 shares. Quantitative Systematic Strategies Limited Liability stated it has 11,794 shares. Moreover, Emerald Advisers Inc Pa has 0.01% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Parallax Volatility Advisers Lp, a California-based fund reported 798 shares. Price T Rowe Assoc Md holds 0% or 83,594 shares in its portfolio.

Since March 19, 2018, it had 0 insider purchases, and 4 insider sales for $425,035 activity. 10,000 Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares with value of $150,000 were sold by Weissman James B.

Analysts expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report $-0.42 EPS on August, 9.They anticipate $0.73 EPS change or 63.48 % from last quarter’s $-1.15 EPS. After having $-0.30 EPS previously, Dicerna Pharmaceuticals, Inc.’s analysts see 40.00 % EPS growth. The stock decreased 4.87% or $0.64 during the last trading session, reaching $12.5. About 337,121 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since July 14, 2017 and is uptrending. It has outperformed by 304.70% the S&P500.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Among 8 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Dicerna Pharmaceuticals had 8 analyst reports since January 16, 2018 according to SRatingsIntel. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Friday, March 9 by Stifel Nicolaus. The firm has “Buy” rating given on Monday, February 5 by SunTrust. The rating was initiated by Cowen & Co with “Buy” on Wednesday, April 11. On Friday, March 9 the stock rating was initiated by Chardan Capital Markets with “Hold”. The firm has “Neutral” rating given on Friday, March 23 by H.C. Wainwright. On Tuesday, March 27 the stock rating was initiated by FBR Capital with “Hold”.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $660.27 million. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More news for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were recently published by: Streetinsider.com, which released: “Dicerna Pharma (DRNA) Reports Recommendation from EMA Committee to Designate DCR-PHXC an Orphan …” on July 11, 2018. Businesswire.com‘s article titled: “Dicerna Set to Join the Russell 3000” and published on June 19, 2018 is yet another important article.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.